COMMUNIQUÉS West-GlobeNewswire

Interim Report Q1 2018: Double digit organic growth drives strong EBITA margin increase. GN Audio upgrades organic growth guidance

02/05/2018 - 07:00

GN Store Nord delivered 10% organic revenue growth in Q1 2018. Revenue growth was 3% including around (7)% impact from development in foreign exchange rates EBITA margin increased 1.1 percentage points in Q1 2018 [...]

Initiation of new share buyback program

02/05/2018 - 06:53

Based on the continued solid business performance and GN’s capital structure policy and in accordance with the authorization granted to the Board of Directors at the annual general meeting on 13 March 2018, GN announces [...]

BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd.

02/05/2018 - 01:00

BEIJING, China and CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted [...]

REVA to Hold First Quarter 2018 Financial Results Call

02/05/2018 - 00:57

SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) has scheduled a conference call to review its first quarter 2018 financial results and provide a business update. The [...]

Onconova Therapeutics Announces Closing of $28.75 Million Upsized Underwritten Public Offering

02/05/2018 - 00:33

Underwriter’s Option to Purchase Additional Securities Exercised in Full NEWTOWN, Pa., May 01, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX ) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical [...]

IntelGenx Announces Proposed Private Placement

01/05/2018 - 23:25

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES SAINT LAURENT, Quebec, May 01, 2018 (GLOBE NEWSWIRE) -- IntelGenx [...]

Aeterna Zentaris to Announce First Quarter 2018 Financial and Operating Results on May 7, 2018

01/05/2018 - 23:05

CHARLESTON, S.C., May 01, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS ) (TSX: AEZS ) will announce its first quarter 2018 financial and operating results after market close on Monday, May 7, 2018. The [...]

National Research Corporation Announces First Quarter 2018 Results

01/05/2018 - 23:00

Company Pivots Clients to Digital Voice of Customer (VOC) Platform LINCOLN, Neb., May 01, 2018 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ: NRC ) today announced results for the first quarter of 2018. [...]

Harvard Bioscience Subsidiary Multi Channel Systems Launches Beta Cell Screening System for Diabetes Research, Entering New Segment of Electrophysiology Market

01/05/2018 - 23:00

Multi-Electrode Array (MEA) Offers New Route for Type 2 Diabetes Drug Development and Ability to Elucidate Beta Cell Pathophysiology HOLLISTON, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Multi Channel Systems (MCS), a [...]

Intercept to Announce First Quarter 2018 Financial Results on May 8, 2018 and Present at Upcoming Investor Conferences

01/05/2018 - 23:00

NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

01/05/2018 - 23:00

EMERYVILLE, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX ), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it [...]

Immunovaccine Shareholders Approve Share Consolidation at 99.85%

01/05/2018 - 22:35

HALIFAX, Nova Scotia, May 01, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV )(OTCQX:IMMVF), a clinical stage immuno-oncology corporation, today announced that at the annual and special meeting of shareholders [...]

Harvard Bioscience Subsidiary Data Sciences International Launches Two Telemetry Implants to Enhance Neuroscience Research

01/05/2018 - 22:30

PhysioTel™ Digital L03 and L04 Designed to Improve Animal Welfare in Large Animal Models ST. PAUL, Minn. and HOLLISTON, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard [...]

Assure Holdings Corp. Announces Update

01/05/2018 - 22:30

PARKER, Colo., May 01, 2018 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “ Company ” or “ Assure ”) (TSXV:IOM) (OTCQB:ARHH) is announcing that the Company has applied for and received a Management Cease Trade Order (“ [...]

Teligent, Inc. to Present at Deutsche Bank’s 43rd Annual Health Care Conference on Tuesday May 8, 2018

01/05/2018 - 22:30

BUENA, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT ), a New Jersey based specialty generic pharmaceutical company, will be presenting at Deutsche Bank’s 43 rd Annual Health Care Conference. The [...]

Avivagen Announces its Attendance at the Bloom Burton & Co. Healthcare Investor Conference

01/05/2018 - 22:30

OTTAWA, May 01, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, [...]

Zafgen to Host Conference Call to Discuss First Quarter 2018 Financial Results

01/05/2018 - 22:30

BOSTON, May 01, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq: ZFGN ), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients [...]

OpGen Announces Date of First Quarter 2018 Financial Results Conference Call

01/05/2018 - 22:30

GAITHERSBURG, Md., May 01, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN ) announced today that the Company will report financial results for the three months ended March 31, 2018 after close of the U.S. financial [...]

Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma

01/05/2018 - 22:27

Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only CAR-T therapy FDA-approved [...]